PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀
null
PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference
null
PolyPid Ltd (PYPD) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
null
PolyPid Q1 Earnings Call Highlights
null
PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results
null
PolyPid (PYPD) Q1 2026 Earnings Transcript
null
PolyPid Q1 2026 Earnings Call: Complete Transcript
null
PolyPid Ltd. Q1 2026 Earnings Call Summary
null
PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026
null
PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting
null
PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026
null
PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA
null
PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀’s New Drug Application
null
PolyPid Announces Participation in Upcoming Investor Conferences
undefined
When Will PolyPid Ltd. (NASDAQ:PYPD) Turn A Profit?
#Product Stage
PolyPid Ltd. Q4 2025 Earnings Call Summary
null
PolyPid (PYPD) Q4 2025 Earnings Call Transcript
#Product Stage #Partners #Management Changes
PolyPid Q4 Earnings Call Highlights
#Product Stage #Partners #Management Changes
PolyPid Ltd (PYPD) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Challenges
#Product Stage #Partners #Management Changes
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
#Product Stage #Partners #Management Changes
PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026
#Product Stage
PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors
#Management Changes
PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission
#Product Stage
PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025
#Product Stage #Partners
PolyPid Ltd (PYPD) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial Challenges
#Product Stage #Partners
PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results
#Product Stage #Partners
PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"
#Product Stage
PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025
#Product Stage #FDA approved/pending approval
PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress
#Product Stage #FDA approved/pending approval
PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference
#Product Stage #Management Changes
PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀
#Product Stage
PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference
#Product Stage #Investment
PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference
#Product Stage #FDA approved/pending approval
PolyPid Ltd (PYPD) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Rising Expenses
#Product Stage #Investment
PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results
#Product Stage #Management Changes #Partners
PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer
#Management Changes #Product Stage
PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025
#Product Stage
PYPD: Positive Topline Data From D-PLEX₁₀₀ Trial Contributes to Multiple Subsequent Benefits
#Product Stage
PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market
#Product Stage
Finance Herald Publishes Coverage of PolyPid's Groundbreaking New 60-Day GLP-1 Delivery Tech
#Product Stage #Acquisition
Analysts Predict Up to ~590% Spike for These 2 ‘Strong Buy’ Penny Stocks
#Product Stage #Investment
PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results
#Investment
The Israeli company's treatment is a delayed-release antibiotic administered in the area where the patient has undergone surgery.
#Product Stage #Partners #Investment
PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints
#Product Stage
Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial
#Product Stage
PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025
#Product Stage
Salesforce initiated, Dollar Tree upgraded: Wall Street’s top analyst calls
#Investment
PYPD: Assessing & Advancing Lead Candidate D-PLEX₁₀₀, Through Clinical Trials to Improve Surgical Outcomes, Enhance Treatment Efficacy, Minimize Side Effects
#Product Stage #FDA approved/pending approval
PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
#Product Stage #Investment
PolyPid Ltd (PYPD) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
#Product Stage #Investment #Partners
PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results
#Product Stage #Partners #Investment
PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025
#Product Stage
PolyPid to Participate in The Citizens Life Sciences Conference
#Product Stage #Investment
Q1 Virtual Investor Summit: On-Demand Presentations Now Live
#Product Stage
PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections
#Product Stage
PolyPid to Participate in the 37th Annual ROTH Conference
#Product Stage #Investment
PolyPid Ltd (PYPD) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising R&D Costs
#Product Stage #Investment #Partners
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results
#Product Stage #Investment #Partners #Management Changes
PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
#Product Stage #Investment
PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025
undefined
PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million
#Investment #Partners
PolyPid Eyes Results From D-PLEX100 Trial in Q2 After Independent Board Gives Nod to Complete Enrollment
undefined
PolyPid announces research, development collaboration with ImmunoGenesis
#Partners
PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy
#Partners
PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance
#Investment #Public Trading
PolyPid Ltd (PYPD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
#Investment #Partners
PolyPid Provides Corporate Update and Reports Third Quarter 2024 Financial Results
undefined
PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference
#Investment
PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024
undefined
PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery
undefined
PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections
#Investment
PolyPid to Participate in Three Upcoming Fall Investor Conferences
#Investment
PolyPid Provides Corporate Update and Reports Second Quarter 2024 Financial Results
#Investment #Management Changes
PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds
#Investment
PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024
#None
PolyPid Hosts KOL Call to Discuss Significant Unmet Medical Need in Surgical Site Infections Prevention and Provides Update on its Ongoing SHIELD II Phase 3 Trial
#Customers #Management Changes
PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company’s Ongoing D-PLEX₁₀₀ Phase 3 Trial
#Management Changes
PolyPid Ltd. (NASDAQ:PYPD) Q1 2024 Earnings Call Transcript
#Investment #Expand
PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results
#Investment
PolyPid to Participate in Citizens JMP Life Sciences Conference
#Management Changes
PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections
#Investment
PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections
#Investment
PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024
#Public Trading
PYPD: Polypid is Enhancing Surgical Outcomes
#Investment #Expand
PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference
#Management Changes
PolyPid Ltd. (PYPD) Upgraded to Buy: What Does It Mean for the Stock?
undefined
PolyPid Ltd. (PYPD) Upgraded to Buy: What Does It Mean for the Stock?
undefined
PolyPid Ltd. (NASDAQ:PYPD) Q4 2023 Earnings Call Transcript
#Investment #Management Changes
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
#Investment
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
#Investment
PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial
#Investment
PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024
undefined
PolyPid Announces Private Placement for $16 Million in Gross Proceeds
#Investment
PolyPid Announces Private Placement for $16 Million in Gross Proceeds
#Investment
PolyPid Ltd. (NASDAQ:PYPD) Q3 2023 Earnings Call Transcript
#Management Changes #Expand
PolyPid Ltd. (NASDAQ:PYPD) Q3 2023 Earnings Call Transcript
#Customers #Management Changes #Expand
PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results
#Management Changes #Investment
PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors
#Management Changes
PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors
#Management Changes
PolyPid to Report Third Quarter 2023 Financial Results and Operational Highlights on November 8, 2023
#Public Trading
PolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
#Public Trading
PolyPid Announces Presentation at the American College of Surgeons Clinical Congress 2023
#Customers
PolyPid Announces Publication of Preclinical Data Further Supporting the Good Safety Profile of D-PLEX₁₀₀ and PLEX Technology Platform
#Investment #Expand
PolyPid to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
#Management Changes
PolyPid Announces Successful Commercial Good Manufacturing Practice (GMP) Audit by Israeli Ministry of Health
#Expand
PolyPid Announces Reverse Share Split
#Public Trading
PolyPid Announces Successful Completion of Manufacturing Process Validation for D-PLEX₁₀₀
#Customers, Expand
PolyPid Provides Corporate Update and Reports Second Quarter 2023 Financial Results
#Customers #Investment
PolyPid to Report Second Quarter 2023 Financial Results and Operational Highlights on August 9, 2023
#Public Trading
PolyPid Announces New Publication Highlighting Potent Antibacterial Activity of D-PLEX₁₀₀ against Susceptible and Resistant Bacteria for the Prevention of Surgical Site Infections
#Investment
PolyPid Announces Recruitment of First Patient in Revised SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections
#Customers
PolyPid Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement and Transfer of its Listing to the Nasdaq Capital Market
#Public Trading
PolyPid Announces FDA Agreement on the Design of SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections
#Expand
PolyPid Ltd. (NASDAQ:PYPD) Q1 2023 Earnings Call Transcript
#Management Changes
PolyPid Provides Corporate Update and Reports First Quarter 2023 Financial Results
#Management Changes #Investment
Sidoti's Micro-Cap Virtual May Conference
#Customers
PolyPid to Report First Quarter 2023 Financial Results and Operational Highlights on May 10, 2023
undefined
PolyPid to Participate in Upcoming Investor Conferences
#Investment
PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance
#Public Trading
PolyPid Announces Closing of Underwritten Public Offering, Including Full Exercise of Overallotment Option, and Concurrent Private Placement with $11.4 Million in Aggregate Gross Proceeds
#Investment #Partners
PolyPid Announces Pricing of $6.2 Million Underwritten Public Offering of Ordinary Shares and Concurrent $4.4 Million Private Placement of Pre-Funded Warrants
#Investment #Public Trading
PolyPid Announces Proposed Underwritten Public Offering of Ordinary Shares
#Public Trading #Investment
PolyPid to Present at the Barclays Global Healthcare Conference
#Public Trading
PolyPid Ltd. (NASDAQ:PYPD) Q4 2022 Earnings Call Transcript
#Management Changes
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
#Investment, Management Changes
PolyPid to Report Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 8, 2023
#Public Trading
PolyPid Provides Positive Regulatory Update for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery
#Investment
PolyPid Announces Publication in the American Journal of Surgery of Phase 2 Clinical Trial Post-hoc Analysis for D-PLEX₁₀₀ in the Prevention of Surgical Site Infections in Abdominal Surgery
#Customers
PolyPid Announces Scheduling of Type D Meeting with U.S. FDA to Discuss SHIELD I Phase 3 Results and Regulatory Pathway for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery | BioSpace
#Customers #Management Changes
PolyPid Announces Scheduling of Type D Meeting with U.S. FDA to Discuss SHIELD I Phase 3 Results and Regulatory Pathway for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery
#Customers
PolyPid Announces Receipt of Nasdaq Minimum Bid Price Notification
#Public Trading
PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the First Triennial Meeting of the International Orthopaedic Trauma Association
#Investment
PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the First Triennial Meeting of the International Orthopaedic Trauma Association
#Customers
PolyPid Announces Eligibility for European Medicines Agency Centralized Procedure for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery
#Customers, Expand
PolyPid Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results for D-PLEX₁₀₀ in the Prevention of Surgical Site Infections in Abdominal Surgery
#Investment
PolyPid plunges 73% after trial disappointment
null
PolyPid Announces Exclusive Licensing Agreement with ADVANZ PHARMA for the Commercialization of D-PLEX₁₀₀ in Europe
#Partners #Investment
PolyPid Announces Planned CEO Transition
#Management Changes
PolyPid Initiates First Phase 3 Clinical Trial of D-PLEX100 for the Prevention of Post-Abdominal Surgery Incisional Infections
#Customers
PolyPid raises $60m at third IPO attempt
#Investment #Public Trading
PolyPid Ltd. Announces Pricing of Initial Public Offering
#Public Trading
Polypid sets terms to raise $50m in Nasdaq IPO
#Public Trading #Investment
PolyPid takes aim at Nasdaq once again
#Public Trading #Investment
PolyPid Announces the Initiation of a Phase 3 Clinical Trial of D-PLEX100 for the Prevention of Sternal Wound Infection Post-cardiac Surgery BioSpace
#Customers, Expand
Drug developer PolyPid to file for Wall Street IPO
#Public Trading #Investment
PolyPid Announces Positive Top-line Results from Phase 2 Clinical Trial of D-PLEX100 for the Prevention of Surgical Site Infections in Abdominal Surgery
#Investment
Drug development co PolyPid raises $50m
#Investment
PolyPid gets a second QIDP designation for D-PLEX100
null
PolyPid Announces FDA Clearance of Investigational New Drug Application (IND) to Commence Pivotal Phase 3 Clinical Trial of D-PLEX[100] for the Prevention of Sternal Wound Infection Post-Cardiac Surgery
#Investment, Expand
Biotech Company Polypid Raises $15 Million
#Investment #Public Trading
Drug release co PolyPid sets terms for $75m Nasdaq IPO
#Investment #Public Trading
Israeli co PolyPid files for $86m Nasdaq IPO
#Investment #Public Trading
FDA fast tracks Israeli co PolyPid
#Investment #Expand
Drug release co PolyPid raises $5.3m
#Investment #Management Changes
Israeli drug development co Polypid raises $22m
#Investment, Management Changes
PolyPid Announces First Patient Enrolled in Confirmatory Clinical Trial, Evaluating Performance and Safety of BonyPid-1000™, an Antibiotic Eluting Bone Void Filler
#Customers
PolyPid revives planned Nasdaq IPO
#Investment #Public Trading
PolyPid sets terms for $20m Nasdaq IPO
#Investment #Public Trading